The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia, Critical and Emergency Care Group
  4. Cochrane Back and Neck Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Common Mental Disorders Group
  10. Cochrane Consumers and Communication Group
  11. Cochrane Cystic Fibrosis and Genetic Disorders Group
  12. Cochrane Dementia and Cognitive Improvement Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Effective Practice and Organisation of Care Group
  16. Cochrane ENT Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
  21. Cochrane Gynaecology and Fertility Group
  22. Cochrane Haematological Malignancies Group
  23. Cochrane Heart Group
  24. Cochrane Hepato-Biliary Group
    1. About this group
    2. Reviews
      1. Abdominal lift for laparoscopic cholecystectomyReview
      2. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis BReview
      3. Aminoadamantanes for chronic hepatitis CReview
      4. Aminoadamantanes versus other antiviral drugs for chronic hepatitis CReview
      5. Anabolic-androgenic steroids for alcoholic liver diseaseReview
      6. Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patientsReview
      7. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleedingReview
      8. Antibiotic prophylaxis for leptospirosisReview
      9. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatographyReview
      10. Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomyReview
      11. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleedingReview
      12. Antibiotic prophylaxis for surgical site infection in people undergoing liver transplantationReview
      13. Antibiotics for leptospirosisReview
      14. Antibiotics for preventing leptospirosisReviewWithdrawn
      15. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patientsReview
      16. Antibiotics for treating leptospirosisReviewWithdrawn
      17. Antibody induction versus corticosteroid induction for liver transplant recipientsReview
      18. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipientsReview
      19. Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver diseaseReview
      20. Antioxidant supplements for liver diseasesReview
      21. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitisReview
      22. Antioxidant supplements for preventing gastrointestinal cancersReview
      23. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseasesReview
      24. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virusReview
      25. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantationReview
      26. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virusReview
      27. Artificial and bioartificial support systems for liver failureReview
      28. Azathioprine for primary biliary cirrhosisReview
      29. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adultsReview
      30. Bariatric surgery for non-alcoholic steatohepatitis in obese patientsReview
      31. Benzodiazepine receptor antagonists for hepatic encephalopathyReview
      32. Bezafibrate for primary biliary cirrhosisReview
      33. Bicyclol for chronic hepatitis BReview
      34. Bicyclol for chronic hepatitis CReview
      35. Bile acids for liver-transplanted patientsReview
      36. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitisReview
      37. Bile acids for primary sclerosing cholangitisReview
      38. Bile acids for viral hepatitisReview
      39. Bisphosphonates for osteoporosis in primary biliary cirrhosisReview
      40. Booster dose vaccination for preventing hepatitis BReview
      41. Branched-chain amino acids for people with hepatic encephalopathyReview
      42. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipientsReview
      43. Capsule endoscopy for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosisReviewDiagnostic
      44. Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resectionReview
      45. Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infectionReview
      46. Chinese medicinal herbs for cholelithiasisReview
      47. Chinese medicinal herbs for chronic hepatitis BReview
      48. Chlorambucil for patients with primary biliary cirrhosisReview
      49. Cholecystectomy deferral in patients with endoscopic sphincterotomyReview
      50. Cholecystectomy for gallbladder polypReview
      51. Cholecystectomy for patients with silent gallstonesReview
      52. Cholecystectomy for suspected gallbladder dyskinesiaReview
      53. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosisReview
      54. Colchicine for primary biliary cirrhosisReview
      55. Cryotherapy for hepatocellular carcinomaReview
      56. Cryotherapy for liver metastasesReview
      57. Cyclosporin A for primary biliary cirrhosisReview
      58. Cyclosporin versus tacrolimus for liver transplanted patientsReview
      59. D-penicillamine for primary biliary cirrhosisReview
      60. D-penicillamine for primary sclerosing cholangitisReview
      61. Day-surgery versus overnight stay surgery for laparoscopic cholecystectomyReview
      62. Dopamine agents for hepatic encephalopathyReview
      63. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisReviewWithdrawn
      64. Early versus delayed laparoscopic cholecystectomy for people with acute cholecystitisReview
      65. Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colicReview
      66. Elective surgery for benign liver tumoursReview
      67. Electro-coagulation for liver metastasesReview
      68. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patientsReview
      69. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stonesReview
      70. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertensionReview
      71. Endoscopic retrograde cholangiopancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgeryReview
      72. Endoscopic retrograde cholangiopancreatography versus intraoperative cholangiography for diagnosis of common bile duct stonesReviewDiagnostic
      73. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography for common bile duct stonesReviewDiagnostic
      74. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patientsReview
      75. Fewer-than-four ports versus four ports for laparoscopic cholecystectomyReview
      76. Formal education of patients about to undergo laparoscopic cholecystectomyReview
      77. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patientsReview
      78. Glucocorticosteroids for primary biliary cirrhosisReview
      79. Glucocorticosteroids for primary sclerosing cholangitisReview
      80. Glucocorticosteroids for viral hepatitis CReview
      81. Hepatitis A immunisation in persons not previously exposed to hepatitis AReview
      82. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothersReview
      83. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure statusReview
      84. Hepatitis B vaccination for patients with chronic renal failureReview
      85. Herbal medicines for fatty liver diseasesReview
      86. Hormone replacement for osteoporosis in women with primary biliary cirrhosisReview
      87. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesReview
      88. Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscessReview
      89. Immunoglobulins for preventing hepatitis AReview
      90. Interferon alpha for chronic hepatitis DReview
      91. Interferon for acute hepatitis CReview
      92. Interferon for interferon naive patients with chronic hepatitis CReview
      93. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CReview
      94. Interventions for paracetamol (acetaminophen) overdoseReview
      95. Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomyReview
      96. Ischaemic pre-conditioning for elective liver resections performed under vascular occlusionReview
      97. Ischaemic preconditioning for liver transplantationReview
      98. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantationReview
      99. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinomaReview
      100. Laparoscopic surgical box model training for surgical trainees with limited prior laparoscopic experienceReview
      101. Laparoscopic surgical box model training for surgical trainees with no prior laparoscopic experienceReview
      102. Laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasisReview
      103. Laparoscopic versus open liver resection for benign and malignant hepatic lesions in adultsReview
      104. Laparoscopic versus small-incision cholecystectomy for patients with symptomatic cholecystolithiasisReview
      105. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastasesReview
      106. Low pressure versus standard pressure pneumoperitoneum in laparoscopic cholecystectomyReview
      107. Medicinal herbs for hepatitis C virus infectionReview
      108. Methods of cystic duct occlusion during laparoscopic cholecystectomyReview
      109. Methods of decreasing infection to improve outcomes after liver resectionsReview
      110. Methods of intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomyReview
      111. Methods of preventing bacterial sepsis and wound complications after liver transplantationReview
      112. Methods of vascular occlusion for elective liver resectionsReviewWithdrawn
      113. Methods of vascular occlusion for elective liver resectionsReview
      114. Methods to decrease blood loss and transfusion requirements for liver transplantationReview
      115. Methods to decrease blood loss during liver resection: a network meta-analysisReview
      116. Methotrexate for primary biliary cirrhosisReview
      117. Microwave coagulation for liver metastasesReview
      118. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseasesReview
      119. Miniports versus standard ports for laparoscopic cholecystectomyReview
      120. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinomaReview
      121. Nitazoxanide for chronic hepatitis CReview
      122. Nonabsorbable disaccharides for hepatic encephalopathyReview
      123. Nutritional interventions for liver-transplanted patientsReview
      124. Nutritional support for liver diseaseReview
      125. Open, small-incision, or laparoscopic cholecystectomy for patients with symptomatic cholecystolithiasis. An overview of Cochrane Hepato-Biliary Group reviewsReviewOverview
      126. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumoursReview
      127. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis CReview
      128. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CReview
      129. Pentoxifylline for alcoholic hepatitisReview
      130. Percutaneous cholecystostomy for high-risk surgical patients with acute calculous cholecystitisReview
      131. Percutaneous ethanol injection for liver metastasesReview
      132. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinomaReview
      133. Percutaneous needle aspiration, injection, and re-aspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cystsReview
      134. Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular controlReview
      135. Pharmacological interventions for prevention or treatment of postoperative pain in people undergoing laparoscopic cholecystectomyReview
      136. Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resectionReview
      137. Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular controlReview
      138. Phyllanthus species for chronic hepatitis B virus infectionReview
      139. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infectionReview
      140. Piggy-back graft for liver transplantationReview
      141. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosisReview
      142. Pre-operative biliary drainage for obstructive jaundiceReview
      143. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitisReview
      144. Probiotics for patients with hepatic encephalopathyReview
      145. Propylthiouracil for alcoholic liver diseaseReview
      146. Prostaglandins for adult liver transplanted patientsReview
      147. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinomaReview
      148. Ribavirin monotherapy for chronic hepatitis CReview
      149. Ribavirin plus interferon versus interferon for chronic hepatitis CReview
      150. Ribavirin with or without alpha interferon for chronic hepatitis CReviewWithdrawn
      151. Robot assistant versus human or another robot assistant in patients undergoing laparoscopic cholecystectomyReview
      152. Routine abdominal drainage for uncomplicated liver resectionReview
      153. Routine abdominal drainage for uncomplicated open cholecystectomyReview
      154. Routine abdominal drainage versus no abdominal drainage for uncomplicated laparoscopic cholecystectomyReview
      155. Routine drainage for orthotopic liver transplantationReview
      156. S-adenosyl-L-methionine for alcoholic liver diseasesReviewWithdrawn
      157. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis BReview
      158. Small-incision versus open cholecystectomy for patients with symptomatic cholecystolithiasisReview
      159. Somatostatin analogues for acute bleeding oesophageal varicesReview
      160. Sphincterotomy for biliary sphincter of Oddi dysfunctionReview
      161. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitisReview
      162. Surgical resection versus liver transplant for patients with hepatocellular carcinomaReview
      163. Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastasesReview
      164. Surgical versus endoscopic treatment of bile duct stonesReview
      165. T-tube drainage versus primary closure after laparoscopic common bile duct explorationReview
      166. T-tube drainage versus primary closure after open common bile duct explorationReview
      167. Tamoxifen for hepatocellular carcinomaReview
      168. Techniques for liver parenchymal transection in liver resectionReview
      169. Techniques of flushing and reperfusion for liver transplantationReview
      170. Terlipressin for acute esophageal variceal hemorrhageReview
      171. Terlipressin for hepatorenal syndromeReview
      172. Three dimensional versus two dimensional imaging for laparoscopic cholecystectomyReview
      173. TIPS versus paracentesis for cirrhotic patients with refractory ascitesReview
      174. Transarterial (chemo)embolisation for unresectable hepatocellular carcinomaReview
      175. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastasesReview
      176. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver diseaseReviewDiagnostic
      177. Ultrasound versus liver function tests for diagnosis of common bile duct stonesReviewDiagnostic
      178. Ursodeoxycholic acid and/or antibiotics for prevention of biliary stent occlusionReview
      179. Ursodeoxycholic acid for primary biliary cirrhosisReview
      180. Vaccines for preventing hepatitis B in health-care workersReview
      181. Vascular occlusion for elective liver resectionsReview
      182. Veno-venous bypass versus none for liver transplantationReview
      183. Virtual reality training for surgical trainees in laparoscopic surgeryReview
      184. Vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseasesReview
      185. Weight reduction for non-alcoholic fatty liver diseaseReview
      186. Wound infiltration with local anaesthetic agents for laparoscopic cholecystectomyReview
    3. Protocols
      1. Acetyl-L-carnitine for patients with hepatic encephalopathyProtocol
      2. Acupuncture for chronic hepatitis B virus infectionProtocol
      3. Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infectionProtocol
      4. Adefovir dipivoxil for chronic hepatitis BProtocol
      5. Adefovir dipivoxil for chronic hepatitis BProtocol
      6. Adefovir dipivoxil versus other antiviral drugs for chronic hepatitis BProtocol
      7. Albumin and other plasma expanders for paracentesis treatment of ascites in cirrhotic patientsProtocol
      8. Anterior approach versus conventional liver resection for hepatocellular carcinomaProtocol
      9. Antibiotics for cholangitis and/or cholecystitisProtocol
      10. Antibiotics for hepatic encephalopathyProtocol
      11. Antiviral agents for hepatitis B virus-related cirrhosisProtocol
      12. Antiviral treatments for lamivudine-resistant chronic hepatitis B adult patientsProtocol
      13. Banding ligation versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in childrenProtocol
      14. Banding ligation versus sclerotherapy for primary prophylaxis of oesophageal varices in childrenProtocol
      15. Banding ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in childrenProtocol
      16. Beta-blocker plus nitrates for secondary prevention of variceal bleedingProtocol
      17. Beta-blockers alone or with endoscopic therapy for prevention of variceal rebleeding in portal hypertensionProtocol
      18. Beta-blockers alone or with isosorbide mononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varicesProtocol
      19. Beta-blockers for prevention of oesophageal variceal rebleeding in cirrhotic patientsProtocol
      20. Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal varices in childrenProtocol
      21. Bile acid derivatives for people with primary biliary cholangitisProtocolNew
      22. Bile acid derivatives for people with primary sclerosing cholangitisProtocolNew
      23. Bile acids for biliary colicProtocol
      24. Carvedilol versus non-selective beta-blockers for portal hypertension in cirrhosisProtocol
      25. Celsior solution versus University of Wisconsin solution in liver preservation for transplantationProtocol
      26. Chemotherapy for gallbladder cancerProtocol
      27. Chinese herbal medicines for adverse events of transarterial chemoembolization in patients with primary liver cancerProtocol
      28. Combination of magnetic resonance cholangiopancreatography and conventional magnetic resonance imaging for the diagnosis of bile duct stenosisProtocolDiagnostic
      29. Comparison of medicinal herbs for chronic hepatitis B virus infectionProtocol
      30. Conversion of calcineurin inhibitor treatment to target of rapamycin inhibitor treatment versus continuation of calcineurin inhibitor treatment for liver transplant recipientsProtocol
      31. Diets for primary prevention of gallbladder stones in adultsProtocol
      32. Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinomaProtocolWithdrawn
      33. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisProtocol
      34. Emergency sclerotherapy or band ligation combined with vasoactive drugs for bleeding esophageal varices in cirrhosisProtocol
      35. Endoscopic interventions for unresectable cholangiocarcinomaProtocol
      36. Entecavir for chronic hepatitis BProtocol
      37. Erythrocytapheresis versus phlebotomy for hereditary haemochromatosisProtocol
      38. External beam radiotherapy for unresectable hepatocellular carcinomaProtocol
      39. Fibrin-based haemostatic agents for reducing blood loss in adult liver resectionProtocol
      40. Forns index and 'FIB4' for staging of fibrosis in adults with chronic hepatitis CProtocolDiagnostic
      41. Foscarnet for chronic hepatitis BProtocol
      42. Gemcitabine-based chemotherapy for advanced biliary tract carcinomasProtocol
      43. Glucocorticosteroids for alcoholic hepatitisProtocol
      44. Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomyProtocol
      45. Glucocorticosteroids for patients undergoing laparoscopic cholecystectomyProtocol
      46. Glucocorticosteroids for viral hepatitis BProtocol
      47. Glycyrrhizin for chronic hepatitis B virus infectionProtocol
      48. Glycyrrhizin versus antiviral drugs for chronic hepatitis B virus infectionProtocol
      49. Granulocyte-colony stimulating factor for acute liver failure or acute-on-chronic liver failureProtocol
      50. Hepatitis B immune globulin for preventing hepatitis B recurrence after liver transplantationProtocol
      51. Hepatitis B immunoglobulin during pregnancy for the prevention of mother to child transmission of hepatitis B virusProtocol
      52. Immunosuppressive regimens for liver transplantation: a network meta-analysisProtocol
      53. Interferon alpha for chronic hepatitis BProtocol
      54. Interferon alpha versus any other drug for chronic hepatitis DProtocol
      55. Interferon beta for chronic hepatitis BProtocol
      56. Interferon for hepatocellular carcinomaProtocol
      57. Interferon gamma for chronic hepatitis BProtocol
      58. Intra-peritoneal saline instillation versus no instillation for laparoscopic cholecystectomyProtocol
      59. Isoprinosine for chronic hepatitis BProtocol
      60. Isoprinosine versus other antiviral drugs for chronic hepatitis BProtocol
      61. L-ornithine-L-aspartate for hepatic encephalopathyProtocol
      62. Lamivudine during pregnancy for preventing hepatitis B virus infection in newbornsProtocol
      63. Lamivudine for chronic hepatitis B in adultsProtocol
      64. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapyProtocol
      65. Laparoscopic-endoscopic rendezvous versus preoperative endoscopic sphincterotomy for common bile duct stones in patients undergoing laparoscopic cholecystectomyProtocol
      66. Levamisole for chronic hepatitis BProtocol
      67. Magnetic resonance imaging, computer tomography scan, and oesophagography for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      68. Management of people with early or very early stage hepatocellular carcinoma: a network meta-analysisProtocol
      69. Management of people with intermediate-stage hepatocellular carcinoma: a network meta-analysisProtocol
      70. Medical therapeutic agents for Wilson's diseaseProtocol
      71. Medical treatments for autoimmune hepatitisProtocol
      72. Medicinal herbs for acute hepatitis BProtocol
      73. Methods of gallbladder dissection for laparoscopic cholecystectomyProtocol
      74. Molecular and antigen detection tests for leptospirosisProtocolDiagnostic
      75. Mycophenolate mofetil for liver-transplanted patientsProtocol
      76. Naloxone for hepatic encephalopathyProtocol
      77. Non-invasive test of liver fibrosis for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      78. Non-steroid anti-inflammatory drugs for biliary colicsProtocol
      79. Nutrition support in hospitalised adults at nutritional riskProtocol
      80. Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver diseaseProtocol
      81. Organic nitrates for prevention of oesophageal varices bleeding and re-bleedingProtocol
      82. Pegylated interferon for acute hepatitis CProtocol
      83. Pegylated interferon for chronic hepatitis BProtocol
      84. Perfusion techniques for liver retrieval in liver donorsProtocol
      85. Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): a network meta-analysisProtocol
      86. Pharmacological interventions for the primary prevention of gallbladder stones in adultsProtocol
      87. Pharmacological interventions to decrease ischaemia reperfusion injury in liver transplantationProtocol
      88. Pharmacological treatments for acute hepatitis B infection: a network meta-analysisProtocol
      89. Pharmacological treatments for acute hepatitis C infection: a network meta-analysisProtocol
      90. Pharmacological treatments for chronic hepatitis B liver disease: a network meta-analysisProtocol
      91. Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysisProtocol
      92. Pharmacological treatments for non-alcohol related fatty liver disease (NAFLD): a network meta-analysisProtocol
      93. Pharmacological treatments for primary biliary cirrhosis: a network meta-analysisProtocol
      94. Pharmacological treatments for primary sclerosing cholangitis: a network meta-analysisProtocol
      95. Phlebotomy for hereditary haemochromatosisProtocol
      96. Platelet count, spleen length, and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      97. Postexposure vaccines for hepatitis AProtocol
      98. Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinomaProtocol
      99. Preoperative physical exercise training for patients scheduled for major abdominal surgeryProtocol
      100. Prostaglandin E1 analogues for chronic hepatitis BProtocol
      101. Protease inhibitors in combination with pegylated interferon and ribavirin for adult patients with chronic hepatitis C virusProtocol
      102. Rifaximin for people with hepatic encephalopathyProtocol
      103. S-adenosyl-L-methionine for people with alcoholic liver diseaseProtocol
      104. Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in childrenProtocol
      105. Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in childrenProtocol
      106. Selective vasopressin type 2 receptor antagonist for patients with cirrhosisProtocol
      107. Serological laboratory tests for diagnosis of human leptospirosis in patients presenting with clinical symptomsProtocolDiagnostic
      108. Sophorus species for chronic hepatitis B virus infectionProtocol
      109. Surgical portosystemic shunts versus devascularisation procedures for variceal bleeding due to hepatosplenic schistosomiasisProtocol
      110. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhageProtocol
      111. Surgical versus medical treatment of refractory ascitesProtocol
      112. Systemic chemotherapy for inoperable hepatocellular carcinomaProtocol
      113. Techniques of biliary reconstruction for liver transplantationProtocol
      114. Telbivudine for chronic hepatitis BProtocol
      115. Terlipressin versus other vasoactive drugs for hepatorenal syndromeProtocol
      116. Thymosin alpha1 for chronic hepatitis BProtocol
      117. Tiopronin for chronic hepatitis BProtocol
      118. Total portosystemic shunt versus shunts preserving portal venous hepatic perfusion for variceal haemorrhageProtocol
      119. Transarterial (chemo)embolisation versus other nonsurgical ablation methods for liver metastasesProtocol
      120. Transient ultrasound elastography and magnetic resonance elastography for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      121. Transjugular intrahepatic portosystemic shunts for hepatorenal syndromeProtocol
      122. Treatments for hereditary haemochromatosis: a network meta-analysisProtocol
      123. Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adultsProtocol
      124. Ultrasonography for diagnosis of cirrhosis in people with alcoholic liver diseaseProtocolDiagnostic
      125. Vitamin D supplementation for chronic liver diseases in adultsProtocol
      126. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinomaProtocol
  25. Cochrane HIV/AIDS Group
  26. Cochrane Hypertension Group
  27. Cochrane IBD Group
  28. Cochrane Incontinence Group
  29. Cochrane Infectious Diseases Group
  30. Cochrane Injuries Group
  31. Cochrane Kidney and Transplant Group
  32. Cochrane Lung Cancer Group
  33. Cochrane Metabolic and Endocrine Disorders Group
  34. Cochrane Methodology Review Group
  35. Cochrane Movement Disorders Group
  36. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group
  37. Cochrane Musculoskeletal Group
  38. Cochrane Neonatal Group
  39. Cochrane Neuromuscular Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Pregnancy and Childbirth Group
  43. Cochrane Public Health Group
  44. Cochrane Schizophrenia Group
  45. Cochrane Skin Group
  46. Cochrane STI Group
  47. Cochrane Stroke Group
  48. Cochrane Tobacco Addiction Group
  49. Cochrane Upper GI and Pancreatic Diseases Group
  50. Cochrane Urology Group
  51. Cochrane Vascular Group
  52. Cochrane Work Group
  53. Cochrane Wounds Group

SEARCH